Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update [Seeking Alpha]
Harrow Health, Inc. (HROW)
Last harrow health, inc. earnings: 11/13 04:21 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
Despite a slight Q3 revenue miss and lowered 2025 guidance ($270M–$280M), operating leverage and commercial expansion underpin a robust growth outlook. Vevye's preferred formulary status and expanded coverage in 2026, alongside Iheezo's strong adoption, set up for accelerating revenue and margin improvement. Bear thesis centers on regulatory risk at ImprimisRx and underperformance in the Rare & Specialty Products portfolio, though management anticipates a rebound. HROW stock is a Buy and I continue to hold my shares patiently. A conservative strategy for entering the stock is shared below. This idea was discussed in more depth with members of my private investing community, ROTY Biotech Community. Learn More » bymuratdeniz/E+ via Getty Images Shares of eyecare specialist Harrow, Inc. ( HROW ) have risen by 219% over the past three years as the company increased its focus on branded products segment and diversified away from its initial compounding business. On More on
Show less
Read more
Impact Snapshot
Event Time:
HROW
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HROW alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HROW alerts
High impacting Harrow Health, Inc. news events
Weekly update
A roundup of the hottest topics
HROW
News
- Breakeven Is Near for Harrow, Inc. (NASDAQ:HROW) [Yahoo! Finance]Yahoo! Finance
- How CVS Elevating Vevye To Tier 1 Coverage At Harrow (HROW) Has Changed Its Investment Story [Yahoo! Finance]Yahoo! Finance
- Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS [Seeking Alpha]Seeking Alpha
- Harrow to Present at Two Investor Conferences in DecemberGlobeNewswire
- Harrow Announces Closing of Acquisition of Melt PharmaceuticalsGlobeNewswire
HROW
Earnings
- 11/10/25 - Beat
HROW
Sec Filings
- 1/8/26 - Form 4
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- HROW's page on the SEC website